Total Payments
$354,536
2024 Payments
$13,977
Companies
11
Transactions
307
Medicare Patients
2,889
Medicare Billing
$213,301
Payment Breakdown by Category
Other$131,148 (37.0%)
Consulting$89,245 (25.2%)
Research$67,832 (19.1%)
Travel$56,903 (16.1%)
Food & Beverage$9,348 (2.6%)
Education$59.35 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $131,148 | 70 | 37.0% |
| Consulting Fee | $89,245 | 35 | 25.2% |
| Unspecified | $67,832 | 25 | 19.1% |
| Travel and Lodging | $56,903 | 97 | 16.1% |
| Food and Beverage | $9,348 | 76 | 2.6% |
| Education | $59.35 | 4 | 0.0% |
Payments by Type
General
$286,703
282 transactions
Research
$67,832
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $159,245 | 148 | $0 (2024) |
| Novo Nordisk AS | $73,426 | 47 | $0 (2022) |
| Eli Lilly and Company | $67,702 | 24 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $30,087 | 46 | $0 (2021) |
| Lilly USA, LLC | $15,166 | 25 | $0 (2022) |
| VERTEX PHARMACEUTICALS INCORPORATED | $7,250 | 9 | $0 (2024) |
| Medtronic MiniMed, Inc. | $1,287 | 3 | $0 (2019) |
| Dexcom, Inc. | $168.01 | 1 | $0 (2018) |
| Amgen Inc. | $85.81 | 1 | $0 (2022) |
| Eisai Inc. | $63.28 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,977 | 12 | Novo Nordisk Inc ($9,882) |
| 2023 | $12,881 | 11 | Novo Nordisk Inc ($10,596) |
| 2022 | $24,679 | 36 | Novo Nordisk Inc ($22,443) |
| 2021 | $17,500 | 23 | Novo Nordisk Inc ($12,669) |
| 2020 | $21,630 | 22 | Novo Nordisk Inc ($8,250) |
| 2019 | $60,258 | 45 | Novo Nordisk Inc ($34,907) |
| 2018 | $121,243 | 68 | Novo Nordisk AS ($46,639) |
| 2017 | $82,368 | 90 | Novo Nordisk Inc ($32,876) |
All Payment Transactions
307 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 10/16/2024 | Novo Nordisk Inc | Victoza (Drug) | Consulting Fee | Cash or cash equivalent | $7,406.25 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Novo Nordisk Inc | Victoza (Drug) | Travel and Lodging | In-kind items and services | $816.42 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Novo Nordisk Inc | Victoza (Drug) | Travel and Lodging | In-kind items and services | $697.96 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Novo Nordisk Inc | Victoza (Drug) | Food and Beverage | In-kind items and services | $461.60 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Novo Nordisk Inc | Victoza (Drug) | Travel and Lodging | In-kind items and services | $342.58 | General |
| Category: Diabetes | ||||||
| 09/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 07/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $124.50 | General |
| 06/21/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $32.42 | General |
| 05/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 01/17/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 01/17/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 11/29/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 11/10/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 11/09/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 11/08/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 09/06/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 06/25/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $122.35 | General |
| 05/31/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $7,593.75 | General |
| 05/31/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $572.17 | General |
| 05/31/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $404.23 | General |
| 05/31/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $28.37 | General |
| 03/02/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $725.00 | General |
| 11/17/2022 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,975.00 | General |
| Category: Diabetes | ||||||
| 11/17/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $124.50 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $33,880 | 4 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION | Eli Lilly and Company | $12,530 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $6,239 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $5,175 | 1 |
| A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE WITH OR WITHOUT METFORMIN | Eli Lilly and Company | $4,882 | 3 |
| EX9924-4473 | Novo Nordisk AS | $1,839 | 8 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,389 | 3 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $1,255 | 1 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $499.66 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $142.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 206 | 296 | $92,810 | $20,390 |
| 2022 | 10 | 926 | 2,433 | $233,688 | $81,640 |
| 2021 | 8 | 885 | 1,285 | $174,277 | $62,257 |
| 2020 | 11 | 872 | 1,057 | $163,261 | $49,014 |
Total Patients
2,889
Total Services
5,071
Medicare Billing
$213,301
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 118 | $32,214 | $8,526 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 36 | 36 | $22,860 | $4,195 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 37 | $15,207 | $3,115 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 39 | $12,955 | $2,267 | 17.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 17 | $8,874 | $2,033 | 22.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 18 | 18 | $450.00 | $161.84 | 36.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 28 | 31 | $250.00 | $93.09 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 301 | 462 | $140,040 | $41,839 | 29.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 1,080 | $23,760 | $18,130 | 76.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 53 | 53 | $20,458 | $6,393 | 31.2% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 43 | 44 | $13,706 | $3,772 | 27.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 58 | 102 | $8,670 | $2,716 | 31.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 21 | $8,469 | $2,689 | 31.8% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 175 | 271 | $6,199 | $2,599 | 41.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 36 | $7,686 | $2,161 | 28.1% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 218 | 343 | $2,219 | $1,095 | 49.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 14 | 21 | $2,481 | $245.94 | 9.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 306 | 470 | $124,770 | $44,644 | 35.8% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 44 | 47 | $14,006 | $4,261 | 30.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 56 | $10,108 | $3,427 | 33.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 20 | 24 | $8,559 | $3,187 | 37.2% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 187 | 266 | $5,586 | $2,583 | 46.2% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 38 | 68 | $5,780 | $1,974 | 34.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2021 | 223 | 338 | $2,028 | $1,096 | 54.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 15 | 16 | $3,440 | $1,087 | 31.6% |
About Dr. Robert Silver, M.D
Dr. Robert Silver, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538268123.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Silver, M.D has received a total of $354,536 in payments from pharmaceutical and medical device companies, with $13,977 received in 2024. These payments were reported across 307 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($131,148).
As a Medicare-enrolled provider, Silver has provided services to 2,889 Medicare beneficiaries, totaling 5,071 services with total Medicare billing of $213,301. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Brooklyn, NY
- Active Since 09/21/2006
- Last Updated 03/28/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1538268123
Products in Payments
- Ozempic (Drug) $50,477
- Tresiba (Drug) $30,230
- Victoza (Drug) $30,005
- FARXIGA (Drug) $23,459
- HUMULIN (Drug) $14,852
- Rybelsus (Drug) $14,091
- Ryzodeg 70/30 (Drug) $13,324
- RYBELSUS (Drug) $12,178
- Xultophy 100/3.6 (Drug) $6,690
- BYDUREON (Drug) $6,628
- Minimed 670G System (Device) $1,250
- Xultophy (Drug) $260.00
- DEXCOM CGM (Device) $168.01
- Prolia (Biological) $85.81
- MOUNJARO (Drug) $69.33
- Lenvima (Drug) $63.28
- t:slim X2 insulin pump (Device) $56.06
- Guardian Connect (Device) $36.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Brooklyn
Dr. Matin Sharafatkhah, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $437,076
Endocrinology, Diabetes & Metabolism $437,076
Dr. Matvey Brokhin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $373,852
Endocrinology, Diabetes & Metabolism $373,852
Alexander Perkelvald, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $343,784
Endocrinology, Diabetes & Metabolism $343,784
Dr. Iraklii Buziashvili, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $122,903
Endocrinology, Diabetes & Metabolism $122,903
Dr. Saka Kazeem, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $23,364
Endocrinology, Diabetes & Metabolism $23,364
Dr. Miroslawa Kudej, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,117
Endocrinology, Diabetes & Metabolism $17,117